Malaria Prevention & Chemoprophylaxis Risk of malaria in Travelers Watcharapong Piyaphanee MD, Board Int Med, CTH, Dip Trav Med, MFTM RCPS (Glasgow) Travel Medicine Research Unit Faculty of Tropical Medicine, Mahidol University Mekong Malaria 1 Red dot = 500 cases 1
Risks to get malaria depend on Estimation of Attack rate Destination (rural/urban/forested area) Duration of stay Activity Climate and season Density of mosquito in specific area The used of insect repellents and bed net Attack Rate = No. of malaria cases among travelers No. of Travelers exposed to malaria risk area Previous study toward malaria risk Malaria Risk Prophylaxis AE Very limited data Many confounding factors Base on reported malaria cases only Travelers at risk are difficult to define and estimate Estimated risk of acquiring malaria Risk in Thailand = 2:100,000 Risk in India = 14.4:100,000 Risk in Gambia = 253:100,000 Risk in Central America/Carribean = 1.3:100,000 Risk in South America = 7.2:100,000 Asking HH, et al. Emerg Infect Dis 2005; 11:434-441 2
Travelers Malaria among foreigners at the HTD (2000-2005) Overall risk of malaria in travelers to Thailand 1:12,254 Year MP neg PF PV Total 2000 43 2 3 48 2001 16 3 0 19 2002 38 1 0 39 2003 19 1 3 23 2004 9 2 4 15 2005 11 0 2 13 Total 136 9 12 Total 21 Cases in 6 years Hill DR, et al. Trans R Soc Trop Med Hyg 1996; 90:680-1 Piyaphanee W, et al. KJP 2006;44:229-32. Country which malaria thought to be acquired in GeoSentinel Surveillance Network Network of Travel/Tropical Medicine institutes since 1996 Thailand Thailand India Cambodia Africa Burma PNG Laos Malaysia Mosambique Unknown = GeoSentinel Site = Network Member Piyaphanee W, et al. KJP 2006;44:229-32. Antimalarial Chemoprophylaxis Pros Reduce chance to get malaria 80-90% Malaria Risk Prophylaxis AE Cons Take risk to develop side effects Not fully protected; limited efficacy against non-falciparum malaria May create false sense of safety Need good compliance 3
Choice of Chemoprophylaxis Chloroquine-sensitive malaria: Chloroquine Chloroquine-resistant malaria Mefloquine Doxycycline Atovaquone/proguanil Mefloquine resistant malaria Doxycycline Atovaquone/proguanil Doxycycline Dosage 1 cap oral once daily Start 2-3 days before travelling and must be continue throughout the travelling period and continue 4 wks after leaving risk area Side effect: abdominal discomfort, N/V photosensitivity Mefloquine Dosage 1 tab oral once a week Start 1-2 week prior and must be continue 4 wks after traveling Side effect: Neuropsychiatric problem, gastrointestinal discomfort Not recommended in patients with epilepsy, psychosis, cardiac arrhythmias Malarone Malarone (Atovaquone/Proguinil) Start 1-2 day after traveling and continue 1 tab once daily throughout the traveling and continue 7 days after leaving risk area Minimal side effect Very Expensive 4
Incidence of ANY adverse event during chemoprophylaxis Incidence of SEVERE adverse event during chemoprophylaxis Study Population MQ C+P Doxy A+P Steffen 1993 Travelers 24 35 - - Boudreau 1993 US Marines 43 46 - - Barret 1996 Travelers 41 41 Nasveld 2000 Australian Defense - - 58 38 Hogh 2000 Travelers - 28-22 Overbosch 2001 Travelers 68 - - 71 Schlagenhaul 2002 Travelers 88 86 84 82 Schlagenhauf P, Malaria chemoprophylaxis. In Keystone JS, et al. Travel Medicine 2004. Study Population Def. MQ C+P Doxy A+P Philips 1996 Australian Interfere ADL 11.2-6.5 - Schlagenhauf 1996 Swiss Interfere ADL 11.2 - - - Barrett 1996 UK Interfere ADL 17 16 - - Steffen 1993 European Interfere ADL 13 16 Hogh 2000 International Stop 2 0.2 Overbosch 2001 International Stop 5-1 Schlagenhaul 2002 International Stop 10.5 12.4 5.9 6.7 Schlagenhauf P, Malaria chemoprophylaxis. In Keystone JS, et al. Travel Medicine 2004. Incidence of SERIOUS* adverse event during chemoprophylaxis Study Population MQ C+P Doxy A+P MacPhearson 1992 Canadian 1/20,000 - Steffen 1993 European 1/10,000 1/13,600 Croft 1993 UK Soldiers 1/6,000 Barrett 1996 UK 1/600 1/1200 Roche Safety 1997 Worldwide 1/20,000 * Hospitalization Malaria Risk Prophylaxis AE Schlagenhauf P, Malaria chemoprophylaxis. In Keystone JS, et al. Travel Medicine 2004. When consider chemoprophylaxis Our Practice Consider individually Is it necessary? Is it safe and effective? Benefit should be outweigh risk Education is very important Travel in Thailand only Chemoprophylaxis is not recommended SBET may not necessary Mosquito bite prevention is essential Aware signs and symptoms of malaria 5
Beyond Thailand... Boat trip to Luang Prabang Slow boat 6-7 hours to Pak Bang Stay overnight 7-8 hours to Luang Prabang Speed boat 3 hours to Pak Bang 1 hour lunch break 3 hours to Luang Prabang Lao PDR Malaria in Mekong region Chemoprophylaxis in Mekong region Extremely low risk in most tourist areas including Vientiane, Luang Prabang, Ankor Wat, Hanoi Malaria risk confine to rural area only Medical facilities are limited in remote area Consider individually Chemoprophylaxis is recommended only in high risk group SBET may be considered in specific cases e.g. lone trekker, adventure travelers Choice of SBET Atovaquone/Proguinil 4 tabs od for 3 days Artesunate 4 tabs od for 3 days plus Mefloquine 3 tabs then 2 tabs 6 hour later 6
Traveler and Risk of malaria Our Practice Risk should be Understood Managed Risk should not be Overestimated or Underestimated Afraid Neglect Travel to Myanmar, Lao, Cambodia or Vietnam Consider individually Chemoprophylaxis is generally not recommended SBET may be considered in specific cases eg lone trekker, adventure travellers Our Practice Travel to High risk area e.g. Africa, PNG Bite prevention is always essential Chemoprophylaxis is generally recommended Any episode of fever during or after the trip should be rule out malaria Southern Sudan ชายแดนไทย-พม า Bombay, India 7
Principles of Malaria Prevention for Travelers A Awareness B Bite prevention C Chemoprophylaxis when appropriate D Early Diagnosis WHO International travel and health 2007. Traveler and Risk of malaria Risk should be Understood Managed Risk should not be Overestimated or Underestimated Afraid Neglect Standby Emergency Treatment (SBET) Standby Emergency Treatment (SBET) SBET is a medication set for treatment of malaria. Not for prevention. Travelers who plan to carry SBET must Understand how and when to use SBET Written instruction is essential Guideline for the use of SBET SBET Regimen for CQ resistance P.f Has been stayed in the malaria risk area for more than 1 week. Fever with/without chill, abdominal pain, N/V, muscle ache, headache Medical services not available within 12-24 hrs. Take medications as prescribed Seek for medical care as soon as possible even after self-treated Malarone (Atovaquone + Proguinil) 4 tab once daily for 3 days (total 12 tablets) Coartem, Riamet (Artemeter + Lumefantrine) 4 tab twice daily for 3 days (total 24 tablets) Artesunate 4 tab once daily for 3 days (total 12 tablets) PLUS Mefloquine 3 tab stat then 2 tab 6 hj later 8
SBET Regimen for CQ resistance P.f Quinine + Tetracycline (Q7T7) Quinine 2 tab oral tid for 7 days Plus Tetracycline (250) 1 cap oral tid+hs for 7 days Thank you for your attention 9